Provid provides medicinal chemistry CRO services, and has an internal drug development program for MS. The company has technical & scientific expertise in the creation and modification of peptidomimetics.

The company generates revenue from its CRO services. It has financed scientific and technical development efforts – mostly for drug development – from NIH (SBIR/STTR, RO-1), “venture philanthropy” from the National Multiple Sclerosis Society via its Fast Forward, LLC subsidiary, and the NJEDA (Edison Fund).

Industry Categories

Industry Biomedical
Sub-industry Drug discovery, Medicinal Chemistry, Contract Research
Focus Areas Autoimmunity, Oncology, CNS
Focus Areas - detailed Celiac disease, Atherosclerosis, Multiple, Sclerosis, Rheumatoid arthritis

Company

Web http://provid.com/
Incubator Princeton Corporate Plaza
Address 7 Deerpark Drive, Suite D, Monmouth Junction, New Jersey, 08852
Phone
Email moc.divorp|noslo.yrag#moc.divorp|noslo.yrag

University

University University of Pennsylvania
Principal Investigator

Products / Services

(Adapted from website)
Provid's internal drug discovery pipeline includes PV-267, our MHC class II DR2 inhibitor for the treatment of multiple sclerosis. This work is being funded in part by Fast Forward, LLC, the venture philanthropy arm of the National Multiple Sclerosis Society. The platform technology of MHC class II inhibition has generated projects and lead compounds that target other autoimmune diseases.  These are directed toward the MHC alleles for DR1- and DR4-associated diseases (e.g., rheumatoid arthritis) as well as DQ alleles associated with celiac disease and type 1 diabetes. In oncology, Provid has discovered PV-1019, a potent, highly selective inhibitor of Chk2 kinase, a target of importance for oncology. This work was done in collaboration with the NCI.  PV-1019 kills tumor cells that are dependent on Chk2, synergizes with DNA-damaging chemotherapeutic agents, and protects normal cells from DNA damage by radiation and chemotherapeutic agents.Other early stage programs target RNA polymerase for infectious disease and F11R for atherosclerosis.  Both are grant-funded projects with academic groups (Rutgers, SUNY Downstate).

Markets

Multiple Sclerosis Drugs

Key People

Gary Olsen, CEO/CSO

Board of Directors

Scientific Advisory Board

Intellectual Property

LinkedIn

[No Facebook or Twitter pages]


Newsfeed



File nameFile typeSize
Provid PV-267 Exec Summary 022416.pdfPDF document866.94 kBInfo
Add a New Comment